Bide Pharmatech Co. Ltd. A - Asset Resilience Ratio
Bide Pharmatech Co. Ltd. A (688073) has an Asset Resilience Ratio of 9.46% as of March 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2020–2025)
This chart shows how Bide Pharmatech Co. Ltd. A's Asset Resilience Ratio has changed over time. See 688073 FCF to total liabilities ratio to measure the company's free cash flow as a share of total liabilities.
Liquid Assets Composition Over Time
This chart breaks down Bide Pharmatech Co. Ltd. A's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see market value of Bide Pharmatech Co. Ltd. A.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CN¥0.00 | 0% |
| Short-term Investments | CN¥240.38 Million | 9.46% |
| Total Liquid Assets | CN¥240.38 Million | 9.46% |
Asset Resilience Insights
- Limited Liquidity: Bide Pharmatech Co. Ltd. A maintains only 9.46% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
Bide Pharmatech Co. Ltd. A Industry Peers by Asset Resilience Ratio
Compare Bide Pharmatech Co. Ltd. A's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Richter Gedeon Vegyészeti Gyár Nyilvánosan Muködo Rt
F:RIG2 |
Drug Manufacturers - Specialty & Generic | 0.20% |
|
JW Pharmaceutical Corp
KO:001067 |
Drug Manufacturers - Specialty & Generic | 8.17% |
|
Jiangsu Hengrui Medicine Co Ltd
SHG:600276 |
Drug Manufacturers - Specialty & Generic | 0.16% |
|
Shijiazhuang Yiling Pharmaceutical Co Ltd
SHE:002603 |
Drug Manufacturers - Specialty & Generic | 11.60% |
|
Guilin Sanjin Pharmaceutical Co Ltd
SHE:002275 |
Drug Manufacturers - Specialty & Generic | 14.80% |
|
Fuan Pharmaceutical Group Co
SHE:300194 |
Drug Manufacturers - Specialty & Generic | 1.34% |
|
DRI Healthcare Trust
TO:DHT-U |
Drug Manufacturers - Specialty & Generic | 13.91% |
|
Hainan Shuangcheng Pharmaceut
SHE:002693 |
Drug Manufacturers - Specialty & Generic | 1.03% |
Annual Asset Resilience Ratio for Bide Pharmatech Co. Ltd. A (2020–2025)
The table below shows the annual Asset Resilience Ratio data for Bide Pharmatech Co. Ltd. A.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 3.97% | CN¥100.01 Million ≈ $14.63 Million |
CN¥2.52 Billion ≈ $368.29 Million |
+0.85pp |
| 2024-12-31 | 3.12% | CN¥75.52 Million ≈ $11.05 Million |
CN¥2.42 Billion ≈ $353.83 Million |
+3.12pp |
| 2023-12-31 | 0.01% | CN¥122.54K ≈ $17.93K |
CN¥2.42 Billion ≈ $353.39 Million |
-0.16pp |
| 2022-12-31 | 0.17% | CN¥3.97 Million ≈ $581.28K |
CN¥2.36 Billion ≈ $345.23 Million |
-7.92pp |
| 2020-12-31 | 8.08% | CN¥43.00 Million ≈ $6.29 Million |
CN¥531.90 Million ≈ $77.83 Million |
-- |
About Bide Pharmatech Co. Ltd. A
Bide Pharmatech Co., Ltd. engages in the research, development, production, and sale of pharmaceutical products in China. Its products are used in life sciences, organic chemistry, analytical chemistry, and other applications. The company was founded in 2007 and is based in Shanghai, China.